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Abstract
Aims/hypothesis Abnormal cannabidiol (Abn-CBD) and
AS-1269574 are potent selective agonists for GPR55 and
GPR119, respectively. The present study evaluated the actions
and ability of these small-molecule agonists to counteract
experimental diabetes in mice.
Methods Diabetes was induced in NIH Swiss mice by five
consecutive daily intraperitoneal injections of 40 mg/(kg body
weight) streptozotocin. Diabetic mice received daily oral
administration of Abn-CBD or AS-1269574 (0.1 μmol/kg)
or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body
weight, food intake, fluid intake, plasma glucose, insulin,
glucose tolerance, insulin release, lipid profile and pancreatic
morphology were examined. Mechanism of action of agonists
was assessed in acute studies using incretin-receptor-knockout
mice.
Results Abn-CBD and AS-1269574 decreased plasma
glucose (20–26%, p < 0.05) and increased circulating
insulin (47–48%, p< 0.05) by 10–28 days, compared with
saline-treated diabetic controls. Food intake and polydipsia
were reduced by both agonists (21–23%, p < 0.05 and
33–35%, p< 0.01, respectively). After 28 days of treatment,
plasma glucagon concentrations were reduced (p < 0.01)
and glucose tolerance was enhanced by 19–44% by
Abn-CBD (p < 0.05 or p < 0.001) and AS-1269574
(p < 0.05 to p < 0.001). Plasma insulin responses were
improved (p< 0.01) and insulin resistance was decreased
(p< 0.05 or p< 0.01) in both Abn-CBD- and AS-1269574-
treated groups. Triacylglycerols were decreased by 19%
with Abn-CBD (p < 0.05) and 32% with AS-1269574
(p < 0.01) while total cholesterol was reduced by 17%
(p< 0.01) and 15% (p< 0.05), respectively. Both agonists
enhanced beta cell proliferation (p< 0.001) although islet
area was unchanged. Acute studies in Gipr- and Glp1r-
knockout mice revealed an important role for the
glucagon-like peptide 1 (GLP-1) receptor in the actions of
both agonists, with the glucose-lowering effects of
Abn-CBD also partly mediated through the glucose-
dependent insulinotropic peptide (GIP) receptor.
Conclusions/interpretation These data highlight the potential
for fatty acid G-protein-coupled receptor-based therapies as
novel insulinotropic and glucose-lowering agents acting partly
through the activation of incretin receptors.
Keywords Beta cell regeneration . Diabetes . Fatty acid
agonists . Glucose homeostasis . G-protein-coupled
receptors . Insulin secretion .Multiple low-dose streptozotocin
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Introduction
NEFAs play a complex role in glucose homeostasis and the
pathogenesis of type 2 diabetes [1] and recent studies have
shown that G-protein-coupled receptors (GPCRs) are
involved in sensing NEFAs [2, 3]. NEFAs have an emerging
role in improving glucose-stimulated insulin release from
pancreatic beta cells and improving insulin sensitivity in liver
and skeletal muscle [4]. GPCRs have different affinities for
fatty acids of varying chain lengths. Thus whereas medium-
and long-chain fatty acids activate GPR40 and GPR120,
short-chain fatty acids are known to serve as ligands for
GPR41 and GPR43 [4]. Furthermore, novel receptors
GPR55 and GPR119 have recently been shown to affect blood
glucose control, and activation of these receptors with novel
synthetic fatty acids may have therapeutic potential for type 2
diabetes [5].
GPR119 has been identified on pancreatic beta cells and
intestinal L cells and K cells and has the ability to enhance
glucose-stimulated insulin release and the secretion of both
glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic peptide (GIP) [6]. These incretin hormones
have a variety of actions in pancreatic islets including
enhancement of insulin biosynthesis and glucose-stimulated
insulin release, stimulation of beta cell proliferation and
inhibition of beta cell apoptosis [7]. GLP-1 additionally
inhibits glucagon secretion [8]. GPR119 has been shown to
bind a variety of lipid-derived ligands, as well as a range of
small synthetic molecules. Several endogenous and synthetic
GPR119 agonists have been shown to exhibit insulin-
secretory properties in clonal beta cells, isolated islets and
in vivo in mice [9, 10]. AS-1269574 is a specific and potent
fatty acid GPR119 agonist that enhances glucose-dependent
insulin secretion [9, 10]. AS-1269574 has also been implica-
ted in GLP-1 secretion and increased proglucagon gene
promoter activity via GPR119 in a mouse L cell line
(GLUTag) [11]. A recent study found that a synthetic
GPR119 agonist (PSN-632408) can enhance beta cell
regeneration, improve islet cell graft survival and augment
plasma active GLP-1 [12]. Previous reports have found that
GPR119 agonists exhibit enhanced potency in vivo in
combination with inhibition of enzymes such as fatty acid
amide hyd ro l a s e inh ib i t o r (URB-597 ) [13 ] o r
dipeptidyl-peptidase-IV (DPP-IV; sitagliptin) [14, 15].
GPR55 is expressed in the central nervous system, ileum,
adipose tissue and endocrine pancreas, being predominantly
on insulin-secreting beta cells [16, 17]. GPR55 was initially
de-orphanised as a cannabinoid receptor and this receptor
binds many cannabinoid compounds. However, some
GPR55 ligands are not cannabinoids and do not bind to either
cannabinoid receptor 1 (CB1) or 2 (CB2) [16]. Cannabidiol
(CBD) is a known GPR55 antagonist and has structural
similarity to cannabinol and Δ9-tetrahydrocannabinol [18].
A range of synthetic CBD analogues have been synthesised,
including abnormal cannabidiol (Abn-CBD), O-1918 and
O-1602, which all act via GPR55 [5]. GPR55 has been
associated with several physiological roles including
anti-inflammatory activity [19], osteoclast function [20],
insulin secretion and glucose homeostasis [17, 21, 22].
GPR55 agonists exhibited insulinotropic properties in clonal
beta cells, isolated islets and in vivo in mice [17, 21, 22], with
Abn-CBD noted as having the maximum potency and
selectivity for GPR55 [21]. A recent study also using mice
found that ablation of the GPR55 receptor increases adiposity
and insulin resistance, selectively decreasing physical activity
[23]. Further studies are required to assess the efficacy of
Abn-CBD administration in the treatment of diabetes and
other obesity-related diseases.
Recently we identified Abn-CBD and AS-1269574 as po-
tent selective agonists for GPR55 and GPR119, respectively;
both agonists exhibited acute glucose-lowering and
insulinotropic properties in mice [9, 21]. In the present study
we have evaluated the long-term glucose-lowering effects of
small-molecule agonists Abn-CBD and AS-1269574 in mice
with diabetes induced by multiple-low-dose streptozotocin
(STZ). To gain further information on the potential mecha-
nism of action of these GPCR agonists, glucose-lowering
and insulin-releasing properties were assessed in vivo using
Gipr- and Glp1r-knockout mice.
Methods
See electronic supplementary material (ESM) Methods for
details of materials.
AnimalsMale NIH Swiss mice (10–16 weeks old) were pur-
chased from Harlan, UK. Gipr-and Glp1r-knockout mice
crossed with the C57BL/6 strain (courtesy of B. Thorens,
Lausanne, Switzerland and D. J. Drucker, Toronto, ON,
Canada) and age-matched control wild-type C57BL/6 mice
were obtained from an in-house breeding colony. The study
was conducted in accordance with the Guide for the Care and
Use of Laboratory Animals (2011) and the UK Animal
(Scientific Procedures) Act 1986 and ARRIVE guidelines
for reporting experiments involving animals [24].
Chronic administration of Abn-CBD and AS-1269574 in
STZ-induced diabetic mice In a long-term study (28 days),
the effects of daily oral administration of Abn-CBD and
AS-1265974 (both at 0.1 μmol/[kg body weight]) [9, 21] or
saline vehicle (0.9% wt/vol. NaCl) were examined in
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multiple-low-dose streptozotocin-induced diabetic NIH Swiss
mice. To induce diabetes, NIH Swiss mice fasted for 4 h
received five consecutive daily intraperitoneal injections of
STZ (40 mg/[kg body weight]). See ESMMethods for further
details.
Acute in vivo effects of Abn-CBD and AS-1269574 in
incretin-receptor-knockout mice Age-matched, non-fasted
Gipr-knockout, Glp1r-knockout and wild-type C57/BL6
mice (n = 6) received an oral injection of glucose alone
(18 mmol/[kg body weight]) or in combination with either
Abn-CBD or AS-1269574 (both at 0.1 μmol/[kg body
weight]). See ESM Methods for further details.
Acute in vivo effects of Abn-CBD and AS-1269574 and
relevant antagonists in lean mice Fasted male lean NIH
Swiss mice received glucose (18 mmol/[kg body weight])
alone or in combination with GPR119 agonist AS1269754
and GPR119 antagonist exendin (9-39) (0.1 μmol/[kg body
weight]) or GPR55 agonist Abn-CBD and GPR55 antagonist
CBD orally or intraperitoneally and glucose/insulin was
measured.
Histology Pancreatic tissues were removed at 28 days and
processed as previously reported [21]. See ESM Methods
for further details.
Biochemical analysis Analysis of blood samples was
undertaken as previously reported [21, 25]. See ESM
Methods for further details.
Statistics Data are expressed as the means±SEM. Results
were compared using the Student’s t test or one-way
Fig. 1 Effect of daily administration of Abn-CBD and AS-1269574 on
body weight (a), food intake (b), fluid intake (c) and plasma glucose (d)
in STZ-induced diabetic mice. Variables were measured before and dur-
ing 28 day treatment with Abn-CBD, AS-1269574 or saline vehicle
(treatment period indicated by the horizontal black bar). Black squares,
non-diabetic mice treated with saline (normal); white circles, STZ-
induced diabetic mice treated with saline vehicle; black triangles, diabetic
mice treated with Abn-CBD; white triangles, diabetic mice treated with
AS-1269574. Values are means ± SEM for sixmice. *p< 0.05, **p< 0.01
and ***p < 0.001 compared with normal mice; +p< 0.05, ++p< 0.01 and
+++p< 0.001 compared with diabetic mice
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Fig. 2 Effect of daily administration of Abn-CBD and AS-1269574 on
non-fasting plasma insulin (a), pancreatic insulin content (b), plasma
glucagon (c) and GLP-1 (d) in STZ-induced diabetic mice. In (a)
variables were measured before and during 28 days of treatment with
Abn-CBD, AS-1269574 or saline vehicle (treatment period indicated by
the horizontal black bar) and in (b–d) theyweremeasured after 28 days of
treatment. Black squares, non-diabetic mice treated with saline (normal);
white circles, STZ-induced diabetic mice treated with saline vehicle;
black triangles, diabetic mice treated with Abn-CBD; white triangles,
diabetic mice treated with AS-1269574. Values are means ± SEM for
six mice. *p< 0.05, **p < 0.01 and ***p< 0.001 compared with normal
mice; +p< 0.05, ++p < 0.01 and +++p < 0.001 compared with diabetic mice
Fig. 3 (a, b) Effect of daily administration of Abn-CBD and
AS-1269574 on glucose tolerance (a) and plasma insulin response to
glucose (b) in STZ-induced diabetic mice fasted for 18 h. OGTT
(18 mmol/[kg body weight]) was conducted 28 days after treatment with
Abn-CBD, AS-1269574 or saline vehicle. (c, d) Plasma glucose (c) and
insulin (d) AUC values for 0–105 min post injection are shown. Black
circles, non-diabetic mice treated with saline (normal); white squares,
STZ-induced diabetic mice treated with saline vehicle; black triangles,
diabetic mice treated with Abn-CBD; black squares, diabetic mice treated
with AS-1269574. Values are means ± SEM for six mice. *p < 0.05,
**p < 0.01 and ***p < 0.001 compared with normal mice; +p < 0.05,
++p< 0.01 and +++p< 0.001 compared with diabetic mice
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ANOVA on Prism graph pad version 5.0. Differences in data
were considered to be statistically significant for p<0.05.
Results
Effect of Abn-CBD and AS-1269574 on food intake, fluid
intake, body weight, non-fasting plasma glucose, insulin,
glucagon and pancreatic insulin contentMultiple-low-dose
STZ lowered body weight by 10% (p < 0.05) (Fig. 1a).
Administration of the GPCR agonists Abn-CBD and AS-
1269574 over 28 days had no effect on body weight. Food
intake was decreased by 21–23% by Abn-CBD (p<0.05) and
AS-1265974 (p<0.05) (Fig. 1b). Non-fasting plasma glucose
was improved by Abn-CBD (20%, p<0.05) and AS-1269574
(26%, p<0.05) (Fig. 1d) while polydipsia was decreased by
33–35% with Abn-CBD (p < 0.01) and AS-1269574
(p<0.01) (Fig. 1c). Non-fasting plasma insulin was increased
by Abn-CBD (47%, p < 0.05) and AS-1269574 (48%,
p<0.05) by 10–28 days (Fig. 2a). This was associated with
increased pancreatic insulin content in both groups treated
with synthetic agonists (p<0.01) (Fig. 2b). Plasma glucagon
was decreased (p<0.05 or p<0.01) and GLP-1 was increased
(p<0.05) in non-fasting terminal plasma by both Abn-CBD
and AS-1269574, compared with measurements in
STZ-treated control mice (Fig. 2c, d).
Effect of Abn-CBD and AS-1269574 on oral glucose
tolerance and insulin sensitivity Daily oral administration
of GPCR agonists for 28 days decreased the glycaemic excur-
sion during an OGTT by 19–44% (Abn-CBD, p<0.05 or
p<0.001) and 23–43% (AS-1269574, p<0.05 or p<0.001)
compared with the control STZ group (Fig. 3a, c). In addition,
Abn-CBD and AS-1269574 augmented glucose-stimulated
insulin by 27–40% (p < 0.05 or p < 0.01) and 35–53%
(p<0.05 or p<0.01), respectively (Fig. 3b, d). Plasma glucose
concentrations and AUC values following injection of exo-
genous insulin were also reduced by Abn-CBD (p<0.05)
and AS-1269574 (p<0.01) after 28 days of treatment (Fig. 4).
Effect of Abn-CBD and AS-1269574 on dual-energy x-ray
absorption measurements and non-fasting plasma lipid
profile Dual-energy x-ray absorption (DEXA) scanning
revealed a decreased body mass in the three groups of
STZ-treated mice (p<0.05) (Fig. 5a), with no effects on body
fat expressed as percentage of body mass (Fig. 5b).
AS-1269574 and Abn-CBD had no effect on body weight or
fat content, compared with STZ-treated controls (Fig. 5a, b).
GPR119 agonist AS-1269574 enhanced both bone mineral
density (6%, p < 0.05) and bone mineral content (13%,
p<0.05), while GPR55 agonist Abn-CBD augmented bone
mineral content (14%, p<0.05) (Fig. 5c, d). After 28 days of
treatment, non-fasting triacylglycerols decreased by 19% with
Abn-CBD (p<0.05) and 32% with AS-1269574 (p<0.01)
compared with diabetic controls (Fig. 6a). Similarly, total
cholesterol was reduced by both Abn-CBD (17%, p<0.01)
and AS-1269574 (15%, p < 0.05) (Fig. 6b), while
AS-1269574 augmented HDL-cholesterol concentrations by
19% (p<0.01) when compared to the lean group (Fig. 6c).
Effect of Abn-CBD and AS-1269574 on islet morphology
Multiple-low-dose STZ-induced diabetes was associated with
diminished insulin-positive beta cells (p<0.001; Fig. 7a, f),
augmented glucagon-positive alpha cells (p < 0.001;
Fig. 7b, g) and decreased GPR119 expression (p< 0.001;
Fig. 7d, h). These islet abnormalities were partially reversed
in Abn-CBD- and AS-1269574 treated groups, with increased
insulin-positive beta cells (p<0.001; Fig. 7a, f) and reduced
glucagon expression in alpha cells (p< 0.01 or p< 0.001;
Fig. 7b, g) when comparing the Abn-CBD- and
AS-1269574-treated mice with saline-treated STZ-induced
diabetic mice. Additionally, administration of Abn-CBD
enhanced GPR55 islet expression (p<0.001; Fig. 7c, h) while
Fig. 4 Effect of daily administration of Abn-CBD and AS-1269574 on
insulin sensitivity depicted in terms of glucose (a) and AUC for glucose
values (b) in STZ-induced diabetic mice. Insulin sensitivity tests (25 U/
[kg body weight]) were conducted after 28 days of treatment with Abn-
CBD and AS-1269574 or saline vehicle. Black squares, non-diabetic
mice treated with saline (normal); white circles, STZ-induced diabetic
mice treated with saline; white triangles, diabetic mice treated with
Abn-CBD; black circles, diabetic mice treated with AS-1269574.
Values are means ± SEM for six mice. **p < 0.01 and ***p< 0.001 com-
pared with normal mice; +p < 0.05 and ++p < 0.01 compared with diabetic
mice
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AS-1269574 increased GPR119 expression (p < 0.001;
Fig. 7d, h), compared with saline-treated STZ controls.
To investigate beta cell proliferation with GPR119 and
GPR55 agonists, Ki-67 was used as a nuclear marker for cel-
lular replication (Fig. 8). Both Abn-CBD and AS-1269574
enhanced the percentage of insulin/Ki-67 co-positive cells
(Fig. 8k–l). Non-diabetic mice treated with saline (0.4%)
and untreated STZ-induced diabetic (0.6%) mice exhibited
minimal beta cell proliferation while insulin/Ki-67 positive
cell counts were significantly enhanced in Abn-CBD (1.8%,
p < 0.001) and AS-1269574 (2.3%, p < 0.001) treatment
groups (Fig. 8m).
Acute effect of Abn-CBD and AS-1269574 in wild-type
C57BL/6 mice and in Gipr- and Glp1r-knockout mice
Administration of GIP or GLP-1 had no biological effects
Fig. 5 Effect of daily
administration of Abn-CBD and
AS-1269574 on total body mass
(a), fat (b), bone mineral density
(c) and bone mineral content (d)
as measured by DEXA scanning
in STZ-induced diabetic mice.
Variables were measured after
28 days of treatment with Abn-
CBD, AS-1269574 or saline
vehicle. Values are means ± SEM
for six mice. *p < 0.05 compared
with non-diabetic mice treated
with saline; +p< 0.05 compared
with diabetic mice
Fig. 6 Effect of daily administration of Abn-CBD and AS-1269574 on
plasma triacylglycerols (a), total cholesterol (b), HDL-cholesterol (c) and
LDL-cholesterol (d) in STZ-induced diabetic mice. LDL-cholesterol was
calculated using the Friedewald equation (LDL-cholesterol = total choles-
terol minus HDL-cholesterol minus [triacylglycerols/2.2]). Variables
were measured after 28 days of treatment with Abn-CBD, AS-1269574
or saline vehicle. Values are means ± SEM for six mice. *p< 0.05 and
**p< 0.01 compared with non-diabetic mice treated with saline; +p< 0.05
and ++p < 0.01 compared with diabetic mice
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in either Gipr-knockout mice or Glp1r-knockout mice,
respectively (Fig. 9b, c, e and f). In contrast, in C57BL/6
mice GIP lowered plasma glucose by 18–24% (p< 0.05 or
p< 0.01) and enhanced glucose-stimulated insulin release
by 26–29% (p< 0.05) (Fig. 9a, d). Similarly, GLP-1 atten-
uated glucose levels by 23–32% (p< 0.05 or p< 0.001) and
stimulated insulinotropic ability by 33–40% (p< 0.01) in
wild-type controls (Fig. 9a, d). In these control mice,
Fig. 7 (a–d) Representative images of immunocytochemical staining for
insulin (a), glucagon (b), GPR55 (c) and GPR119 (d) in the pancreas of
STZ-induced diabetic mice after 28 days of treatment with Abn-CBD,
AS-1269574 or saline vehicle. Magnification × 40. (e–h) Islet area (e) and
relative fluorescence for insulin (f), glucagon (g), GPR55 and GPR119
(h) determined using cell F software. Values are means ± SEM for six
mice, 25 islets per group. ***p< 0.001 compared with non-diabetic mice
treated with saline; ++p< 0.01 and +++p< 0.001 compared with diabetic
mice
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GPR55 agonist Abn-CBD decreased glucose by 16–27%
(p < 0.05 or p < 0.01) and increased insulin secretion by
29–31% (p < 0.01) (Fig. 9a, d) . GPR119 agonist
AS-1269574 had a similar effect, reducing glucose by
15–22% (p < 0 .05 or p < 0 .01 ) and augmen t i ng
glucose-stimulated insulin release by 35–37% (p < 0.01)
(Fig. 9a, d).
In Gipr-knockout mice, the glucose-lowering and
insulinotropic actions of Abn-CBD were diminished while
AS-1269574 decreased the glycaemic excursion by 14–24%
(p<0.05 or p<0.01) and enhanced glucose-induced insulin
secretion by 33–35% (p<0.01) (Fig. 9b, e). Both Abn-CBD
and AS-1269574 had diminished glucose-lowering and
insulinotropic effects in Glp1r-knockout mice (Fig. 9c, f).
Acute effect of GPR119 and GPR55 agonists in the
presence of antagonistsAS-1269574 administered in combi-
nation with antagonist exendin (9-39) resulted in a 44%
increase in blood glucose (p<0.01) (Fig. 10) while insulin
release was reduced by 39% (p<0.001) (Fig. 10) when com-
pared with AS-1269574 alone. In the presence of GPR55
antagonist CBD and Abn-CBD, glucose increased 49%
(p<0.01), compared with levels noted with agonist alone
(Fig. 11). Insulin levels were reduced by 61% (p<0.001)
using AUC data (Fig. 11), when Abn-CBD was administered
in combination with GPR55 antagonist CBD.
Discussion
Much interest has been focused recently on fatty acid GPCRs
in relation to their potential beneficial effects on glucose
homeostasis in type 2 diabetes and other obesity-related
diseases [1–3, 26]. Several novel fatty acid receptors,
including GPR55 and GPR119, have shown promise as
emerging targets of diabetes therapies. Previous research has
highlighted the potent acute glucose-lowering and
insulinotropic ability of the GPCR agonists Abn-CBD and
AS-1269574 [9, 21] and our acute in vivo studies, using
GPR55 and GPR119 antagonists, have confirmed the
specificity of Abn-CBD and AS-1269574 in islets.
The present study evaluated the glucose-lowering and
insulinotropic properties of small-molecule agonists
Abn-CBD and AS-1269574 in multiple-low-dose
STZ-induced diabetes in mice. This is a commonly employed
means of inducing diabetes [27, 28], which in the present
study was associated with decreased body weight,
hyperphagia, polydipsia, moderate hyperglycaemia,
hyperglucagonaemia and hypoinsulinaemia but with good
numbers of surviving functional beta cells, representing a
model of mild type 1 diabetes. Daily oral administration of
Abn-CBD and AS-1269574 lowered plasma glucose, plasma
glucagon and food and fluid intake. In harmony with this,
plasma insulin and pancreatic insulin content were increased
in both treatment groups. Following long-term administration
Fig. 8 Immunocytochemical
staining for insulin and Ki-67 in
the pancreas of STZ-induced
diabetic mice after 28 days of
treatment with Abn-CBD, AS-
1269574 or saline vehicle. (a–l)
Representative images are shown
for insulin (a–d), Ki-67 (e–h) and
merged insulin and Ki-67 (i–l)
Magnification × 40. (m)
Percentage of Ki-67-positive beta
cells. Values are means ± SEM for
six mice, 25 islets per group.
***p< 0.001 compared with non-
diabetic mice treated with saline;
+++p< 0.001 compared with
diabetic mice. Arrows indicate
insulin/Ki-67 co-positive beta
cells
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of the agonists, glucose tolerance and insulin sensitivity were
markedly improved. Additionally, total cholesterol and
triacylglycerols were decreased by Abn-CBD and
AS-1269574 and HDL-cholesterol was augmented by
AS-1269574. Interestingly, our data would suggest a link
between GPCR activation and suppression of hyperphagia.
We found that GPR55 and GPR119 agonists decreased food
consumption and appetite, though we observed no effect on
overall body weight. This is in contrast to some published
literature suggesting a link between GPR55 antagonism and
reduced food consumption and body weight gain [22]. The
accompanying decrease in fluid intake in the mice in our study
most likely reflects the improved hyperglycaemic status
following treatment with the two GPCR agonists. Moreover,
GPR55 expression has been found to be increased in adipose
tissue of obese individuals and further so in obese patients
with type 2 diabetes, with GPR55 expression correlating with
body weight, BMI and percentage fat mass [29]. Ex vivo
studies using both adipose tissue explants and differentiated
primary adipocytes show that L-α-lysophosphatidylinositol,
an endogenous GPR55 agonist, increased the expression of
genes stimulating fat deposition in adipose tissue and in dif-
ferentiated adipocytes from visceral fat of obese patients it
raised intracellular Ca2+ concentration. The GPR119 data is
generally consistent with a recent study which found that
AS-1907417, a modified form of AS-1269574, improved
lipid profile, plasma insulin, plasma glucose and pancreatic
insulin content over a 4 week treatment period in db/db mice
[30]. These recent studies suggest that activation of GPR55
and GPR119 could play a role in weight management, energy
load and lipid metabolism.
Very few previous studies have assessed long-term admin-
istration of AS-1269574 and Abn-CBD in animal models of
diabetes. Interestingly, bone mineral content, assessed by
DEXA, was increased by agonising GPR119 with
AS-1269574. GPR55 is expressed on osteoclasts [20] and,
in contrast to our observations, GPR55-receptor-knockout
mice have been reported to exhibit enhanced quantity and
Fig. 9 Acute effect of Abn-CBD and AS-1269574 on glucose tolerance,
and the plasma insulin response to oral glucose in C57BL/6 wild-type
mice (a, d) and in C57BL/6 mice with knockout of Gip (b, e) or Glp1
receptors (c, f). Plasma glucose (a–c) and insulin (d–f) were determined
before and after oral administration of glucose (18 mmol/[kg body
weight]) alone or in combination with Abn-CBD or AS-1269574
(0.1 μmol/[kg body weight]). Black circles, glucose; white squares, glu-
cose + GIP (25 nmol l−1 kg−1); black squares, glucose + GLP-1
(25 nmol l−1 kg−1); white circles, glucose +Abn-CBD (0.1 μmol l−1
kg−1); black triangles, glucose + AS-1269574 (0.1 μmol l−1 kg−1).
Values are means ± SEM for six mice. *p < 0.05, **p < 0.01 and
***p< 0.001 compared with 18 mmol/l glucose
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thickness of trabecular bone [20]. This difference may reflect
an adaptive response in mice deficient in GPR55. No data are
currently available on GPR119 and bone metabolism. Of in-
terest, recent studies have highlighted the importance of GIP
[31] and GLP-1 receptors [32] in bone physiology, including
bone strength and quality. This may explain the enhancement
in bone mineral density and content by the GPCR agonists in
this study as the receptors, in particular GPR119, has been
implicated in GIP and GLP-1 secretion [6, 33, 34].
In the present study, multiple-low-dose STZ induced a
relatively moderate form of diabetes associated with
hypoinsulinaemia and mild effects on islet architecture. The
islets contained good numbers of surviving positively stained
insulin beta cells, increased numbers of glucagon-secreting
alpha cells and decreased expression of the GPR119 receptor.
Oral administration of Abn-CBD or AS-1269574 resulted in
increased numbers of insulin-secreting beta cells and reduced
hyperglucagonemia confirmed by decreased circulating
Fig. 10 Acute effect of GPR119
agonist in combination with
GPR119 antagonist exendin (9-
39) on plasma glucose (a, c) and
plasma insulin (b, d). Fasted male
lean NIH Swiss mice (n = 6)
received glucose (18 mmol/[kg
body weight]) alone or in
combination with GPR119
agonist AS1269754 and/or
GPR119 antagonist exendin (9-
39) (0.1 μmol/[kg body weight]).
Values are means ± SEM. Black
circles, glucose alone; white
squares, glucose +AS-1269574;
black triangles, glucose + exendin
(9-39); black squares, glucose +
AS-1269574+ exendin (9-39).
*p< 0.05, **p< 0.01 and
***p< 0.001 compared with
glucose; +p< 0.05, ++p< 0.01 and
+++p< 0.001 compared with
glucose +AS-1269574
Fig. 11 Acute effect of GPR55
agonist in combination with
GPR55 antagonist CBD on
plasma glucose (a, c) and plasma
insulin (b, d). Fasted male lean
NIH Swiss mice (n = 6) received
glucose (18 mmol/[kg body
weight]) alone or in combination
with GPR55 agonist Abn-CBD
and/or GPR55 antagonist CBD.
Black circles, glucose alone;
white squares, glucose +Abn-
CBD; black triangles, glucose +
CBD; black squares, glucose +
Abn-CBD+CBD. Values are
means ± SEM. **p< 0.01 and
***p< 0.001 compared with
glucose; ++p< 0.01 and
+++p< 0.001 compared with
glucose +Abn-CBD
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plasma glucagon levels. The expression of GPR55 and
GPR119 was enhanced by Abn-CBD and AS-1269574,
respectively, with GPR119 reverting to normal expression
levels. In addition, treatment with GPR55 and GPR119
agonists augmented beta cell proliferation and regeneration.
Consistent with this, a recent study reported that the GPR119
agonist PSN-632408 increased GLP-1 secretion and beta cell
proliferation as assessed by Ki-67 and BrdU staining; these
effects were further augmented byDPP-IV inhibitor sitagliptin
[14].Many factors are known to play a role in the regulation of
beta cell proliferation, including incretins, and further studies
are required to investigate the possibility of parallel changes in
apoptosis and to discover whether the increased cellular
proliferation and replication observed in this study with
long-term administration of GPCR agonists is a result of the
action of incretins on beta cell proliferation and beta cell
function. Both GIP and GLP-1 have been implicated in a
number of protective functions in pancreatic beta cells
including proliferation, neogenesis and anti-apoptosis [35].
This study has confirmed [6, 33, 34] that GPR119 agonists
stimulate the release of GLP-1 from L cells. The GPR55
agonist Abn-CBD exhibited potent glucose-lowering and
insulin-releasing properties in C57BL/6 wild-type mice,
effects that were abolished in both Gipr- and Glp1r-knockout
mice. The GPR119 agonist AS-1269574 displayed strong
glucose-lowering and insulinotropic ability in wild-type
C57BL/6 mice as well as Gipr-knockout mice. In contrast,
GPR119 activation with AS-1269574 removed the
glucose-lowering effect of the ligand inGlp1r-knockout mice.
These data indicate that, in addition to direct stimulatory
effects of the agonists on beta cells, the beneficial effects of
Abn-CBD also involve the GIP and GLP-1 receptors and
AS-1269574 activation of the GLP-1 receptor.
Overall these results indicate that GPCR small-molecule
agonists Abn-CBD and AS-1269574 exert a broad spectrum
of actions on glucose homeostasis, islet and enteroendocrine
cells, lipid profiles and pancreatic and bone composition.
Interestingly, few studies have assessed the role of GPR55 in
diabetes [16, 18], with no literature probing the involvement
of incretin hormones in the mechanism of action of GPR55. In
contrast, several studies have identified the importance of
GLP-1 [11, 12, 14, 15] and GIP [6] in GPR119 activation in
glucose homeostasis. Similar to the findings of this study, the
GPR119 agonist AS-1269574 has also been found to enhance
plasma GLP-1 concentrations [11, 34]. Few studies have
assessed the role of GPR119 in GIP signalling and the exact
molecular mechanisms remain unclear. The synthetic agonist
AR-231453 enhanced both GIP and GLP-1 levels in
wild-type mice but not in Gpr119-knockout mice [34].
Additionally, AR-231453 stimulated GIP and GLP-1 release
in wild-type mice and Glp1r- and Gipr-knockout mice [6].
Further studies are clearly warranted to assess the role of
GPR119 and GPR55 agonists on the incretin pathway.
In conclusion, long-term administration of GPR55 agonist
Abn-CBD and GPR119 agonist AS-1269574 improved
glycaemic control in a multiple-low-dose STZ-induced mouse
model of diabetes, resulting in decreased plasma glucose and
glucagon and improved plasma insulin, GLP-1 and lipid
profiles. Additionally, glucose tolerance and insulin sensitivity
were enhanced, with positive actions on the pancreas and
bone. The results also indicate an important action through
the incretin pathway, suggesting that agonists capable of
agonising both fatty acid GPCRs and incretin secretion may
have therapeutic potential in the future.
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